Costs and outcomes associated with IVF using recombinant FSH

REPRODUCTIVE BIOMEDICINE ONLINE

卷:19

Article

Ledger, W.³  Wiebinga, C.⁴  Anderson, P.¹  Irwin, D.²  Holman, A.¹  Lloyd, A.¹ 

[1] IMS Hlth London, London, England

[2] Univ N Carolina, Chapel Hill, NC USA

[3] Royal Hallamshire Hosp, Ctr Reprod Med & Fertil, Sheffield S10 2JF, S Yorkshire, England

[4] NV Organon, NL-5340 BH Oss, Netherlands

关键词: cost;    GnRH antagonist;    ICSI;    IVF;    rFSH;   

DOI  :  10.1016/S1472-6483(10)60167-8

来源: Elsevier

【 摘 要 】

Cost and outcome estimates based oil clinical trial data may not reflect usual clinical practice, yet they are often used to inform service provision and budget decisions. To expand understanding of assisted reproduction treatment in clinical practice, an economic evaluation of IVF/intracytoplasmic sperm injection (ICSI) data from a single assisted conception unit (ACU) in England was performed. A total of 1418 IVF/ICSI Cycles undertaken there between October 2001 and January 2006 in 100 1 women were analysed. The overall live birth rate was 22% (95% CI: 19.7-24.2), with the 30- to 34-year age group achieving the highest rate (28%). The average recombinant FSH (rFSH) dose/cycle prescribed was 1855 IU. Average cost of rFSH/cycle was 646 pound (SD: 219) pound, and average total cost/cycle was 2932 pound (SD: 422) pound. Economic data based on clinical trials informing current UK guidance assumes higher doses of rFSH dose/cycle (1750-2625 IU), higher average cost of drugs/cycle (1179) pound, and higher average total cost/cycle (3266) pound. While the Outcomes in this study matched UK averages, total cost/cycle was lower than those cited in UK guidelines. Utilizing the protocols and (lower) rFSH dosages reported in this study may enable other ACU to provide a greater number of IVF/ICSI cycles to patients within given budgets.

【 授权许可】

Free